AbbVie Inc (ABBV)vsCareCloud, Inc. (CCLD)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
CCLD
CareCloud, Inc.
$2.35
-2.08%
HEALTHCARE · Cap: $99.86M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 50505% more annual revenue ($62.82B vs $124.14M). CCLD leads profitability with a 7.9% profit margin vs 5.8%. CCLD appears more attractively valued with a PEG of 0.31. CCLD earns a higher WallStSmart Score of 66/100 (B-).
ABBV
Buy63
out of 100
Grade: C+
CCLD
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Margin of Safety
+58.0%
Fair Value
$5.33
Current Price
$2.35
$2.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Growing faster than its price suggests
Earnings expanding 5739.0% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Smaller company, higher risk/reward
7.9% margin — thin
Operating margin of 3.4%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : CCLD
The strongest argument for CCLD centers on PEG Ratio, EPS Growth, Debt/Equity. Revenue growth of 13.2% demonstrates continued momentum. PEG of 0.31 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : CCLD
The primary concerns for CCLD are Market Cap, Profit Margin, Operating Margin.
Key Dynamics to Monitor
CCLD carries more volatility with a beta of 1.60 — expect wider price swings.
CCLD is growing revenue faster at 13.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
CCLD scores higher overall (66/100 vs 63/100) and 13.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
CareCloud, Inc.
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
CareCloud, Inc., a healthcare information technology (IT) company, provides a suite of cloud-based solutions and related business services to healthcare providers and hospitals primarily in the United States. The company is headquartered in Somerset, New Jersey.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?